by Tomas J. Philipson in The National Review Capital Matters
“The Inflation Reduction Act’s Medicare price controls create bad incentives for drug development and access.
This month, the Biden administration announced the initial ten drugs, of an eventual total of at least 60, that will be subject to new price controls under the Inflation Reduction Act (IRA). The selection illustrates what goes wrong when government bureaucrats try to control prices rather than enhance competition.”
Read the full article in the National Review.